Panagora Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Panagora Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$532K	Buy	466,519 +230,408	+98%	+$274K	﹤0.01%	886
2026 Q1	$328K	Hold	236,111	–	–	﹤0.01%	947
2025 Q4	$380K	Sell	236,111 -53	-0%	-$111	﹤0.01%	935
2025 Q3	$645K	Buy	236,164 +25,959	+12%	+$86.4K	﹤0.01%	744
2025 Q2	$765K	Buy	+210,205	New	+$578K	﹤0.01%	689
2022 Q3	–	Sell	-250,894	Closed	-$89K	–	1430
2022 Q2	$89K	Hold	250,894	–	–	﹤0.01%	1444
2022 Q1	$180K	Buy	250,894 +233	+0.1%	+$499	﹤0.01%	1471
2021 Q4	$566K	Buy	250,661 +846	+0.3%	+$2.31K	﹤0.01%	1171
2021 Q3	$719K	Buy	249,815 +179,229	+254%	+$512K	﹤0.01%	1130
2021 Q2	$268K	Buy	+70,586	New	+$238K	﹤0.01%	1568
2020 Q4	–	Sell	-30,487	Closed	-$77K	–	2799
2020 Q3	$77K	Buy	+30,487	New	+$268K	﹤0.01%	1910
2018 Q2	–	Sell	-130,574	Closed	-$1.24M	–	2367
2018 Q1	$1.24M	Sell	130,574 -15,970	-11%	-$223K	﹤0.01%	1078
2017 Q4	$2.18M	Buy	146,544 +116,418	+386%	+$1.93M	0.01%	847
2017 Q3	$593K	Hold	30,126	–	–	﹤0.01%	1303
2017 Q2	$433K	Buy	+30,126	New	+$382K	﹤0.01%	1394
2016 Q1	–	Sell	-112,620	Closed	-$1.46M	–	2287
2015 Q4	$1.46M	Sell	112,620 -16,524	-13%	-$169K	0.01%	922
2015 Q3	$1.25M	Buy	129,144 +24,987	+24%	+$229K	0.01%	933
2015 Q2	$1.07M	Buy	104,157 +101,284	+3,525%	+$864K	0.01%	1065
2015 Q1	$32K	Buy	+2,873	New	+$30.6K	﹤0.01%	2149

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Panagora Asset Management's AKBA Position: Q2 2026 in Review

Panagora Asset Management increased its Akebia Therapeutics (AKBA) stake by 98% in Q2 2026, buying an estimated $274K and bringing the position to 466,519 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Panagora Asset Management first reported a position in AKBA in Q1 2015 and has held it in 19 quarters since. The position peaked at $2.18M in Q4 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Panagora Asset Management held 466,519 shares of Akebia Therapeutics worth $532K as of Q2 2026.
Panagora Asset Management bought 230,408 Akebia Therapeutics shares in Q2 2026, an estimated $274K.
Akebia Therapeutics made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #886 holding.
Panagora Asset Management first reported a position in Akebia Therapeutics in Q1 2015 and has held it in 19 quarters since.
Panagora Asset Management's Akebia Therapeutics position peaked at $2.18M in Q4 2017.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.